Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

10.1002/cpdd.427

Saved in:

Bibliographic Details
Main Authors:	Tan, Eng-Huat, Lim, Wan-Teck, Ahn, Myung-Ju, Ng, Quan-Sing, Ahn, Jin Seok, Tan, Daniel Shao-Weng, Sun, Jong-Mu, Han, May, Payumo, Francis C, Mckee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	WILEY 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy ficlatuzumab NSCLC gefitinib lung adenocarcinoma non-small cell lung cancer CELL LUNG-CANCER ADVANCED SOLID TUMORS FACTOR RECEPTOR CLINICAL-SIGNIFICANCE SCATTER-FACTOR RESISTANCE MET MUTATIONS ERLOTINIB ADENOCARCINOMA
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218636
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Be the first to leave a comment!